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To pursue a borderline increased risk of breast cancer for carriers of two integrin beta3 (ITGB3) 33Pro alleles found in a recent
prospective study, we conducted a case–control study of 1088 women with breast cancer and 4815 female controls. Leu33Pro
heterozygotes, homozygotes and heterozygotesþhomozygotes vs noncarriers had odds ratios for breast cancer of 1.0 (95%
confidence interval: 0.8–1.1), 0.8 (0.5–1.2) and 1.0 (0.8–1.1), respectively. After stratification for conventional risk factors, odds ratio
for breast cancer in heterozygotes, homozygotes and heterozygotesþhomozygotes vs noncarriers were not increased above 1.0 in
any of the 14 strata examined. This was also true after stratification for tumour histological subtype and cancer stage at the time of
diagnosis.
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In a recent large prospective study of the general population, we
demonstrated an increased risk of all cancer among integrin
beta3 (ITGB3) Leu33Pro homozygotes (Bojesen et al, 2003). It is
unclear as to which cancer subtype(s) account for this;
however, subanalyses suggested that this risk increase partly could
be caused by an increased risk of invasive breast cancer, ovarian
cancer and/or melanoma. Although two later case–control studies
did not confirm an increased risk of invasive breast cancer among
Leu33Pro homozygotes (Ayala et al, 2003; Jin et al, 2004), certain
considerations nevertheless favour the possibility that the ITGB3
Leu33Pro polymorphism may influence risk of invasive breast
cancer. First, beta3 integrins are ectopically expressed on breast
carcinoma cells where they enhance invasive and metastasiogenic
properties of these cells (Murthy et al, 1996; Wewer et al, 1997;
Chen et al, 2001, 2004; Rolli et al, 2003). Second, the Pro33 vs
Leu33 allele enhances integrin-mediated activation of MAPK
pathways (Vijayan et al, 2003), crucial for the malignant potential
of cancer cells (Johnson and Lapadat, 2002). Third, in our previous
prospective study there appeared to be a gene–dosage relationship
as Leu33Pro heterozygotes and homozygotes vs noncarriers had
hazard ratios for invasive breast cancer of 1.2 (95% confidence
interval: 0.9–1.7) and 1.9 (1.0–3.7).
For this reason, we tested the hypothesis that ITGB3 Leu33Pro
heterozygosity and homozygosity have an increased risk of
invasive breast cancer. Given the prospective data, the assumption
of a dominant genetic effect seems reasonable, so we also
combined the heterozygous and the homozygous participants in
one group vs noncarrier participants. We recruited 1088 con-
secutive female patients with invasive breast cancer and compared
these with 4815 women from the general population without breast
cancer. This large case–control study also allowed us to search for
genotype-associated increased risk of breast cancer in women
stratified for conventional risk factors, and to determine whether
genotype-associated breast cancer risk is restricted to certain
histological subtypes or cancer stages.
MATERIALS AND METHODS
Study populations
Cases of invasive breast cancer in women (n¼1088) were
consecutively collected from the Department of Breast Surgery,
Herlev University Hospital from 2001 to 2004. Owing to centralised
breast cancer care, this department covers all cases of invasive
breast cancer in roughly half of the Greater Copenhagen area, a
population amounting to 320000 women the 1st of January 2004.
All patients filled in a questionnaire on lifestyle and health,
including reproductive, menstrual and hormonal history, alcohol
consumption, height and weight. Premenopausal women were
defined as women who had a menstrual period within the previous
2 months. Postmenopausal women had a period more than 12
months ago. If the menstrual period was 2–12 months, the level of
follicular-stimulating hormone decided whether the patient was
pre- or postmenopausal. Furthermore, women 455 years of age
after hysterectomy or with menstruation on hormonal substitution
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informations were missing for 546 women. However, for test of the
main hypothesis (genotype association with risk of breast cancer
adjusted for age), full information was available on all 1088 breast
cancer cases.
Histological classification of tumours according to the WHO
classification (Scarff and Torloni, 1968) and histological grading
according to Bloom and Richardson (1957) was performed by
pathologists blinded to patient genotype. Grade of malignancy of
tumours with ductal histology was scored according to Scarff,
Bloom and Richardson (Bloom and Richardson, 1957; Scarff and
Torloni, 1968). Oestrogen and progesterone receptor status were
determined with immunohistochemistry. An examination was
positive if at least 10% of the nuclei in malignant tissue presented
with typical staining for oestrogen and/or progesterone receptors.
Owing to delay in registration, we did not have information on all
these characteristics for 278 women.
The controls were women recruited from the other half of the
Greater Copenhagen area from the 3rd examination (1991–94) of
the Copenhagen City Heart Study (Appleyard et al, 1989; Schnohr
et al, 2001). Age and other covariates used in the statistical models
were recorded at this examination. Cases of breast cancer
registered until the end of 2002 in the Danish Cancer Registry
were excluded from the controls. In both cases and controls,
497% were whites of Danish descent.
Ethical approvals
All participants gave written informed consent. The scientific
ethical committee of Copenhagen and Frederiksberg approved the
collection of controls (No. 100.2039/91), and the scientific ethical
committee of the County of Copenhagen approved the collection
of cases (KA 02152). The studies were also approved by Herlev
University Hospital.
Genotyping
Participants were genotyped as described earlier (Zimrin et al,
1990). In short, the Leu33Pro polymorphism is a T-C substitu-
tion in exon 3 at position 176 in the beta3 integrin gene (GenBank
Accession no. NM000212.1), which introduces an MspI recognition
site. The assay also included a second MspI recognition site always
cleaved, which served as a control site for the digestion reaction. A
268bp fragment of exon 3 was amplified from genomic DNA with
flanking intronic primers, cleaved with MspI, run on a 3% agarose
gel and visualised by staining with ethidium bromide. Genotypes
were determined independently by an experienced lab technician
and an author (SEB).
Statistical analysis
The statistical software package STATA (2004) was used. All
statistical tests were two-sided. Po0.05 was considered statistically
significant. We used Mann–Whitney U-test and Pearson’s w
2 test.
Correction for multiple comparisons was by the Bonferoni
method. We used NCSS 2001 and PASS 2000 power calculation
software (Hintze, 2001) and a logistic regression power analysis to
calculate the statistical power of this study.
We performed a matched case–control study with strata of 1, 3
and 5 years of age. This resulted in 63 one-year strata with a mean
of 4.5 controls per case, 22 three-year strata and 4.5 controls per
case and 14 five-year strata and 4.6 controls per case, respectively.
Using 1-year strata, two cases both aged 93 were unmatched with
controls and 168 controls aged less than 28 were unmatched with
cases. Conditional logistic regression was used to calculate odds
ratio for invasive breast cancer according to genotype. Two models
were applied: an age-matched model and an age-matched model
also adjusted multifactorially for body mass index (continuous),
alcohol consumption (continuous), parity (0 vs more childbirths),
use of oral contraceptive pill (yes/no), menopausal status (pre- vs
postmenopausal) and use of hormonal replacement therapy (yes/
no). In the analysis of histological subtype and invasive breast
cancer stage, each subtype/stage was compared to the controls with
the age-matched model of 1-year age strata while excluding cases
without the analysed subtype/stage.
RESULTS
Characteristics of participants are shown in Table 1. In cases and
controls, 768 (71%) and 3385 (70%) were noncarriers, 296 (27%)
and 1300 (27%) were heterozygotes and 24 (2%) and 130 (3%)
were homozygotes, respectively. These genotype distributions were
both in Hardy–Weinberg equilibrium (P¼0.67 and 0.70).
Age-matched odds ratios for breast cancer in heterozygotes,
homozygotes and heterozygotesþhomozygotes vs noncarriers
were 1.0 (95% confident interval: 0.8–1.1), 0.8 (0.5–1.2) and 1.0
(0.8–1.1), respectively (Table 2). Identical analyses with age strata
of 3 and 5 years for matching of cases and controls gave similar
results. Multifactorial adjustment did not substantially change
these odds ratios. We had 90% statistical power to detect odds
ratios equal to or larger than 1.3, 1.8 and 1.3 in heterozygous,
homozygous and heterozygousþhomozygous vs noncarriers,
respectively.
To explore whether genotype interacts with conventional risk
factors for breast cancer, we stratified the age-matched and
multifactorially adjusted analyses by age, body mass index,
alcohol consumption, parity, use of oral contraceptive pills,
menopausal status and use of hormonal replacement therapy.
Risk of breast cancer in homozygotes, heterozygotes and hetero-
zygousþhomozygous vs noncarriers was not increased above 1.0
in any of the 14 subgroups of women examined (Figure 1).
Although the adjusted odds ratio in homozygotes vs noncarriers
among women with alcohol consumption 448gweek
 1 was 0.3
(0.1–0.9), this association became nonsignificant after correcting
for multiple comparisons. Furthermore, this association was
Table 1 Characteristics of participants
Invasive breast cancer Controls P-value
Number 1088 4815 —
Age (years) 62 (29–93) 61 (22–90) o0.0001
Body mass index (kgm
 2) 24 (14–51) 24 (13–50) 0.0001
Alcohol consumption (gweek
 1) 48 (0–720) 36 (0–960) 0.0002
Nulliparous (%) 13 (11–16) 25 (24–26) o0.0001
Use of oral contraceptive pill (%) 3 (1–4) 4 (4–5) 0.02
Postmenopausal (%) 76 (73–79) 71 (69–72) 0.0009
Use of hormonal replacement therapy (%) 31 (27–34) 16 (15–17) o0.0001
Values represent median (range) or frequencies (95% confidence interval). P-values are for invasive breast cancer vs controls on Mann–Whitney U-test or Pearson’s w
2 test.
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statistical power.
Risk of breast cancer in homozygotes, heterozygotes and
heterozygousþhomozygous vs noncarriers did not differ from
1.0 in any histological subgroup of invasive breast cancer Table 3.
Risk of invasive breast cancer in homozygotes, heterozygotes
and heterozygousþhomozygous vs non-carriers did not differ
from 1.0 in any cancer stage subgroup (Table 4).
DISCUSSION
So far, four papers have been published on this polymorphism and
breast cancer risk (Ayala et al, 2003; Bojesen et al, 2003; Jin et al,
2004; Wang-Gohrke and Chang-Claude, 2004). Our own first study
was explorative in nature and found a hazard ratio in hetero-
zygotes and homozygotes vs noncarriers of 1.2 (0.9–1.6) and 1.9
(1.0–3.7), P-value 0.06, so this could represent a chance finding. In
Table 2 Risk of invasive breast cancer by ITGB3 Leu33Pro genotype
Odds ratio (95% CI)
Strata Cases/controls
Noncarriers
33Leu/Leu
Heterozygotes
33Leu/Pro
Homozygotes
33Pro/Pro
Heterozygotes
and homozygotes
combined
Age matched 1 year 1086/4647 1.0 1.0 (0.8–1.1) 0.8 (0.5–1.2) 1.0 (0.8–1.1)
3 years 1086/4715 1.0 1.0 (0.8–1.1) 0.8 (0.5–1.3) 1.0 (0.8–1.1)
5 years 1088/4755 1.0 1.0 (0.8–1.1) 0.8 (0.5–1.2) 1.0 (0.8–1.1)
90% power to detect
a — 1.3 1.8 1.3
Multifactorially adjusted
b 1 year 540/4397 1.0 1.1 (0.9–1.4) 0.9 (0.5–1.6) 1.1 (0.9–1.3)
3 years 540/4397 1.0 1.1 (0.9–1.4) 1.0 (0.5–1.7) 1.1 (0.9–1.3)
5 years 540/4455 1.0 1.1 (0.9–1.4) 0.9 (0.5–1.6) 1.1 (0.9–1.3)
90% power to detect
a — 1.4 2.1 1.4
ITGB3¼integrin beta3;C I¼confidence interval.
aThe smallest odds ratios our study (with 1-year age strata) could detect with 90% statistical power and Po0.05 on two-sided
tests.
bIncluding body mass index (continuous), alcohol consumption (continuous), parity (0 vs more childbirths), use of oral contraceptive pill (yes/no), menopausal status (pre- vs
postmenopausal), use of hormone replacement therapy (yes/no).
All
Age 60 years 
Age >60 years
BMI 25 kg m−2 
BMI >25 kg/m−2
Nulliparous
Parous
Premenopausal
Postmenopausal
Alcohol 48 g week−1
Alcohol >48 g week−1
No use of hormone replacement therapy
Use of hormone replacement therapy
No use of oral contraceptive pill
Use of oral contraceptive pill
Stratification ITGB3
Leu33Pro
0.1 0.2 0.4 1.0 2.0 4.0
Age matched Multifactorially adjusted
0.1 0.2 0.4 1.0 2.0 4.0
Odds ratio (95% confidence interval) for breast cancer 
Cases/controls
1086/4647
500/2143
586/2504
476/2618
276/2029
100/1042
687/3566
250/1244
761/3403
314/2714
372/1933
495/3837
221/748
620/4434
16/140
Noncarriers
Heterozygotes
Homozygotes
Combined
Noncarriers
Heterozygotes
Homozygotes
Combined
Noncarriers
Heterozygotes
Homozygotes
Combined
Noncarriers
Heterozygotes
Homozygotes
Combined
Noncarriers
Heterozygotes
Homozygotes
Combined
Noncarriers
Heterozygotes
Homozygotes
Combined
Noncarriers
Heterozygotes
Homozygotes
Combined
Noncarriers
Heterozygotes
Homozygotes
Combined
Noncarriers
Heterozygotes
Homozygotes
Combined
Noncarriers
Heterozygotes
Homozygotes
Combined
Noncarriers
Heterozygotes
Homozygotes
Combined
Noncarriers
Heterozygotes
Homozygotes
Combined
Noncarriers
Heterozygotes
Homozygotes
Combined
Noncarriers
Heterozygotes
Homozygotes
Combined
Noncarriers
Heterozygotes
Homozygotes
Combined
Figure 1 Risk of invasive breast cancer by ITGB3 Leu33Pro genotype. Number of cases/controls refer to the 1-year age strata calculations and vary
through stratifications due to incomplete information on the stratification in question. Multifactorial adjustment was for body mass index (continuous),
alcohol consumption (continuous), parity (0 vs more childbirths), use of oral contraceptive pill (yes/no), menopausal status (pre- vs postmenopausal) and use
of hormone replacement therapy (yes/no).
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cancer in heterozygotes vs noncarriers in a case–control study of
100 cases and 100 controls. However, genotype distribution among
controls was not in Hardy–Weinberg equilibrium (P¼0.048) and
the finding was only significant at P¼0.04, so this also could
represent a chance finding. In a third study (Jin et al, 2004), no
increased (or decreased) risk was found in heterozygotes or
homozygotes. In the fourth study (Wang-Gohrke and Chang-
Claude, 2004) of 602 cases and 1054 controls, the odds ratios for
heterozygotes, homozygotes and heterozygotesþhomozygotes vs
noncarriers were 1.1 (0.9–1.4), 1.3 (0.7–2.4) and 1.1 (0.9–1.4),
respectively. A borderline (P¼0.055) interaction between age
(age p45 vs 445 years) and genotype (noncarriers vs hetero-
zygotesþhomozygotes) with an odds ratio of heterozygo-
tesþhomozygotes vs noncarriers of 1.3 (1.0–1.8) in women aged
over 44 years; in our study, no such interaction could be detected
(P¼0.64). They also detected no association between tumour stage
or grade and genotype (noncarrier vs heterozygousþhomozygous
state) after correcting for multiple comparisons.
Like the previous studies mentioned, the present study has
certain limitations. Covariates for controls were recorded at the
1991–1994 examination, while those for the cases were recorded at
the time of diagnosis in 2001–2004, approximately 10 years apart.
For conventional risk factors such as the use of hormonal
replacement therapy, this could distort risk estimations, but will
not invalidate analyses of genetic risk factors, as genotypes are
permanent. Although cases and controls were recruited from
slightly different geographical locations of the greater Copenhagen
area, the background population is the same, more than 97% being
white women of Danish descent in both cases and controls.
Table 3 Risk of invasive breast cancer by ITGB3 Leu33Pro genotype stratified for histological subtype
Noncarriers 33Leu/Leu Heterozygotes 33Leu/Pro Homozygotes 33Pro/Pro Heterozygotes and homozygotes combined
Histological
subtype n (%) Odds ratio N (%)
Odds
ratio (95%CI) N (%)
Odds ratio
(95%CI) N (%)
Odds ratio
(95%CI)
Ductal 457 (70) 1.0 180 (28) 1.0 (0.8–1.2) 14 (2) 0.7 (0.4–1.3) 194 (30) 1.0 (0.8–1.2)
Lobular 72 (68) 1.0 32 (30) 1.2 (0.8–1.8) 2 (2) 0.7 (0.2–2.9) 34 (32) 1.1 (0.7–1.7)
Others 37 (76) 1.0 12 (24) 0.8 (0.4–1.6) 0 (0) — 12 (24) 0.8 (0.4–1.5)
Unknown 202 (72) 1.0 70 (25) 0.9 (0.7–1.2) 8 (3) 0.9 (0.4–2.0) 78 (28) 0.9 (0.7–1.2)
All 768 (71) 1.0 294 (27) 1.0 (0.8–1.1) 24 (2) 0.8 (0.5–1.2) 318 (29) 1.0 (0.8–1.1)
ITGB3¼integrin beta3;C I¼confidence interval. Odds ratios were vs 4647 controls and matched for age in one-year strata.
Table 4 Risk of invasive breast cancer by ITGB3 Leu33Pro genotype stratified for characteristics of tumour or dissemination at diagnosis
Noncarriers 33Leu/Leu
Heterozygotes 33Leu/
Pro Homozygotes 33Pro/Pro
Heterozygotes and
homozygotes combined
n (%) Odds ratio n (%)
Odds ratio
(95%CI) n (%)
Odds ratio
(95%CI) n (%)
Odds ratio
(95%CI)
Tumour size (mm)
p10 99 (70) 1.0 43 (29) 1.1 (0.8–1.6) 1 (1) 0.2 (0.0–1.7) 44 (31) 1.0 (0.7–1.4)
11–20 217 (68) 1.0 95 (30) 1.1 (0.9–1.4) 5 (2) 0.6 (0.2–1.4) 100 (32) 1.1 (0.8–1.4)
21–30 163 (73) 1.0 53 (24) 0.8 (0.6–1.2) 8 (4) 1.2 (0.6–2.5) 61 (27) 0.9 (0.6–1.2)
31–50 62 (68) 1.0 27 (30) 1.2 (0.7–1.9) 2 (2) 0.9 (0.2–3.6) 29 (32) 1.2 (0.7–1.8)
450 26 (76) 1.0 8 (24) 0.8 (0.4–1.9) 0 (0) — 8 (24) 0.8 (0.3–1.7)
Unknown 201 (73) 1.0 68 (25) 0.9 (0.7–1.2) 8 (3) 0.9 (0.4–2.0) 76 (27) 0.9 (0.7–1.2)
Grade of malignancy (only ductal histology)
Grade I 109 (66) 1.0 52 (31) 1.2 (0.8–1.7) 5 (3) 1.1 (0.4–2.7) 57 (34) 1.2 (0.8–1.6)
Grade II 226 (72) 1.0 83 (26) 1.0 (0.7–1.2) 6 (2) 0.7 (0.3–1.5) 89 (28) 0.9 (0.7–1.2)
Grade III 110 (72) 1.0 40 (26) 0.9 (0.7–1.4) 3 (2) 0.6 (0.2–2.0) 37 (27) 0.9 (0.6–1.3)
Unknown 12 (71) 1.0 5 (29) 1.1 (0.4–3.1) 0 (0) — 5 (29) 0.9 (0.3–2.7)
Hormone receptor status
Negative 95 (71) 1.0 36 (27) 1.0 (0.7–1.5) 2 (2) 0.4 (0.1–1.7) 38 (29) 0.9 (0.6–1.4)
Positive 449 (69) 1.0 186 (29) 1.1 (0.9–1.3) 13 (2) 0.7 (0.4–1.3) 199 (31) 1.0 (0.9–1.2)
Unknown 224 (73) 1.0 72 (24) 0.8 (0.6–1.1) 9 (3) 1.0 (0.5–2.0) 81 (27) 0.8 (0.6–1.1)
Lymph node involvement
No tumour positive nodes 278 (71) 1.0 104 (26) 1.0 (0.8–1.2) 11 (3) 1.0 (0.5–1.8) 115 (29) 1.0 (0.8–1.2)
Tumour-positive nodes, without
breakthrough of capsule
154 (73) 1.0 56 (26) 0.9 (0.7–1.3) 2 (1) 0.3 (0.1–1.2) 58 (27) 0.9 (0.6–1.2)
Tumour-positive nodes, with
breakthrough of capsule
128 (67) 1.0 61 (32) 1.2 (0.9–1.7) 3 (2) 0.6 (0.2–1.9) 64 (33) 1.2 (0.9–1.6)
Unknown 208 (72) 1.0 73 (25) 0.9 (0.7–1.2) 8 (3) 0.9 (0.4–1.9) 81 (28) 0.9 (0.7–1.2)
Distant metastases
Absent 535 (70) 1.0 212 (28) 1.0 (0.9–1.2) 16 (2) 0.7 (0.4–1.2) 228 (30) 1.0 (0.8–1.2)
Present 4 (67) 1.0 2 (33) 1.3 (0.2–7.3) 0 (0) — 2 (33) 1.2 (0.2–6.7)
Unknown 229 (72) 1.0 80 (25) 0.9 (0.7–1.2) 8 (3) 0.8 (0.4–1.7) 88 (28) 0.9 (0.7–1.1)
ITGB3¼integrin beta3;C I¼confidence interval. Odds ratios were vs 4647 controls and matched for age in one-year strata.
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indicates that ITGB3 Leu33Pro heterozygosity and homozygosity
do not increase the risk of breast cancer.
Future research should no longer focus on risk of breast
cancer in ITGB3 Leu33Pro homozygotes, but should rather try
to examine other cancer subgroups like ovarian cancer, melanoma
or yet other cancer subgroups (Bojesen et al, 2003), as explana-
tions for the increased overall cancer risk in Leu33Pro homo-
zygotes.
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